These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 7028558)

  • 1. Improvement of metabolic control in insulin dependent diabetics treated with the alpha-glucosidase inhibitor acarbose for two months.
    Gérard J; Luyckx AS; Lefebvre PJ
    Diabetologia; 1981 Nov; 21(5):446-51. PubMed ID: 7028558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha-Glucosidase inhibition improves postprandial hyperglycemia and decreases insulin requirements in insulin-dependent diabetes mellitus.
    Dimitriadis GD; Tessari P; Go VL; Gerich JE
    Metabolism; 1985 Mar; 34(3):261-5. PubMed ID: 3883097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term treatment in diabetics with acarbose, a glucosidase inhibitor: efficacy, tolerability and effect on GI hormones.
    Hillebrand I; Aubell R; Boehme K; Bloom SR; Berchtold P
    Tohoku J Exp Med; 1983 Dec; 141 Suppl():683-6. PubMed ID: 6393444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acarbose treatment of sulfonylurea-treated non-insulin dependent diabetics. A double-blind cross-over comparison of an alpha-glucosidase inhibitor with metformin.
    Johansen K
    Diabete Metab; 1984 Oct; 10(4):219-23. PubMed ID: 6391973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved metabolic profiles in insulin-treated diabetic patients given an alpha-glucosidehydrolase inhibitor.
    Walton RJ; Sherif IT; Noy GA; Alberti KG
    Br Med J; 1979 Jan; 1(6158):220-1. PubMed ID: 369651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
    Hayakawa T; Noda A; Kondo T; Okumura N
    Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
    Dimitriadis G; Karaiskos C; Raptis S
    Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Acarbose--a new therapeutic principle in diabetes mellitus therapy].
    Schöffling K; Hillebrand I
    Dtsch Med Wochenschr; 1981 Aug; 106(35):1083-4. PubMed ID: 6114844
    [No Abstract]   [Full Text] [Related]  

  • 9. Long-term effects of intestinal alpha-glucosidase inhibition on postprandial glucose, pancreatic and gut hormone responses and fasting serum lipids in diabetics on sulphonylureas.
    Uttenthal LO; Ukponmwan OO; Wood SM; Ghiglione M; Ghatei MA; Trayner IM; Bloom SR
    Diabet Med; 1986 Mar; 3(2):155-60. PubMed ID: 2951158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of chronic alpha-glycosidase inhibition on diabetic nephropathy in the db/db mouse.
    Lee SM
    Diabetes; 1982 Mar; 31(3):249-54. PubMed ID: 6759241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of carbohydrate-induced hypertriglyceridemia in (fa,fa) "Zucker" rats by the alpha-glucosidase inhibitor acarbose (BAY g 5421).
    Krause HP; Keup U; Thomas G; Puls W
    Metabolism; 1982 Jul; 31(7):710-4. PubMed ID: 7045575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic relationships of Acarbose.
    Salvatore T; Giugliano D
    Clin Pharmacokinet; 1996 Feb; 30(2):94-106. PubMed ID: 8906894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic potential of alpha-glucosidase-inhibitors.
    Fölsch UR
    Hepatogastroenterology; 1982 Apr; 29(2):47-8. PubMed ID: 7044933
    [No Abstract]   [Full Text] [Related]  

  • 14. Acarbose: an alpha-glucosidase inhibitor.
    Martin AE; Montgomery PA
    Am J Health Syst Pharm; 1996 Oct; 53(19):2277-90; quiz 2336-7. PubMed ID: 8893066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of the alpha-glucosidase-inhibitor BAY-g-5421 on blood glucose control of sulphonylurea-treated diabetics and insulin-treated diabetics.
    Sachse G; Willms B
    Diabetologia; 1979 Nov; 17(5):287-90. PubMed ID: 387504
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness of acarbose, an alpha-glucosidase inhibitor, in uncontrolled non-obese non-insulin dependent diabetes.
    Buchanan DR; Collier A; Rodrigues E; Millar AM; Gray RS; Clarke BF
    Eur J Clin Pharmacol; 1988; 34(1):51-3. PubMed ID: 3282895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood glucose concentrations and glycosuria during and after one year of acarbose therapy.
    Aubell R; Boehme K; Berchtold P
    Arzneimittelforschung; 1983; 33(9):1314-8. PubMed ID: 6357206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
    Clissold SP; Edwards C
    Drugs; 1988 Mar; 35(3):214-43. PubMed ID: 3286212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. alpha-Glucosidase inhibition in obesity.
    William-Olsson T
    Acta Med Scand Suppl; 1985; 706():1-39. PubMed ID: 3914827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined use of guar and acarbose in reduction of postprandial glycaemia.
    Jenkins DJ; Taylor RH; Nineham R; Goff DV; Bloom SR; Sarson D; Alberti KG
    Lancet; 1979 Nov; 2(8149):924-7. PubMed ID: 91023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.